DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 403 Original 2023 Regular Session Brown

Abstract: Authorizes substitution of biosimilar biological products designated by the federal Food and Drug Administration (FDA).

Present law establishes certain requirements for implementation of step therapy or fail first protocols used by any health coverage plan.

Present law does not prohibit a health coverage plan's substitution of an AB-rated generic equivalent or interchangeable biological product as designated by the FDA.

Proposed law further adds that a health coverage plan is not prohibited from substituting a biosimilar biological product as designated by the FDA. Otherwise retains present law.

(Amends R.S. 22:1053(A)(2))